cpx-351 versus intensive induction chemo in pts with taml or aml with myelodysplasia-related changes
Published 2 months ago • 106 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
3:11
intensive chemotherapy: why the modern approach of cpx-351 is important for cure in aml
-
3:07
improved understanding of cpx-351 in aml: impact of hct & final eap results
-
1:12
cpx-351 and gemtuzumab ozogamicin in r/r aml and mds
-
3:48
cpx-351 for secondary aml: pharmacokinetics, administration & impact on treatment
-
2:36
intensive induction chemotherapy vs hma/ven in npm1-mutant aml: a retrospective study
-
1:02
aml19: flag-ida vs cpx-351 in patients with aml with adverse risk cytogenetics
-
1:55
cardiotoxicity of cpx-351 vs 7 3 chemotherapy in patients with untreated high-risk aml
-
0:52
a real-world study of the optimal duration of cpx-351 treatment in patients with aml
-
9:57
introducing cn-3500/cn-6500
-
7:08
what does real-world data tell us about frontline therapy with cpx-351 vs ven aza?
-
5:09
what do you see as the future of aml treatments? #aml
-
2:01
analyzing the cost-effectiveness of cpx-351 in patients with aml
-
1:19
predicting the outcomes of patients with aml treated with cpx-351 based on eln risk stratification
-
1:47
choosing between cpx-351 and flag-ida in newly diagnosed and r/r aml
-
0:36
the promise of cpx-351 in secondary aml
-
1:55
long-term real-world experience of cpx-351 in patients with t-aml and mrc-aml
-
2:11
cpx-351 plus venetoclax in patients with newly-diagnosed high-risk aml
-
1:08
the real-world safety and efficacy of cpx-351 in patients with aml
-
2:30
outcomes of patients with de-novo vs secondary aml treated with cpx-351
-
3:20
safety run-in of a phase ii trial of cpx-351 plus pomalidomide in aml with mds-related changes
-
2:02
outcomes of cpx-352 vs. 7 3 for t-aml
-
1:30
evaluating the optimal duration of cpx-351 treatment & best timing for allosct consolidation in aml